Optical diagnosis of colorectal polyps: a randomized controlled trial comparing endoscopic image enhancing modalities

2020 ◽  
Author(s):  
Roupen Djinbachian ◽  
Etienne Marchand ◽  
Heiko Pohl ◽  
Andres Aguilera-Fish ◽  
Mickael Bouin ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Colorectal Polyps ◽  
Optical Diagnosis ◽  
Randomized Controlled ◽  
Endoscopic Image ◽  
Image Enhancing

scholarly journals Abstract Near-Focus Versus Normal-Focus Narrow Band Imaging Colonoscopy in Diagnosis of ColorectalPolyps Based on Combined NICE and WASP Classification in Routine Colonoscopy: A Randomized Controlled Trial

2021 ◽  
Author(s):  
Nisa Netinatsunton ◽  
Natcha Cheewasereechon ◽  
Tanawat Pattarapuntakul ◽  
Jaksin Sottisuporn ◽  
Kanet Kanjanapradit ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Narrow Band ◽  
Narrow Band Imaging ◽  
Controlled Trial ◽  
Colorectal Polyps ◽  
Optical Diagnosis ◽  
Serrated Polyps ◽  
Randomized Controlled ◽  
Group A ◽  
Group B

Abstract Near-focus versus Normal-focus Narrow Band Imaging Colonoscopy in Diagnosis of Colorectal Polyps based on Combined NICE and WASP Classification in routine colonoscopy: a Randomized Controlled TrialNisa Netinatsunton1, Natcha Cheewasereechon1Tanawat Pattarapuntakul1, Jaksin Sottisuporn1, Kanet Kanjanapradit2, Bancha Ovartlarnporn1Background: NICE (NBI International Colorectal Endoscopic) and WASP (Workgroup on Serrated Polyps and Polyposis) classification were developed for optical diagnosis of adenoma and sessile serrated polyps, respectively. Near focus NBI with NICE combined with WASP criteria for optical diagnosis of colonic polyps has not been assessed formerly. Aims: To compare the accuracy of near focus NBI (group A) with normal focus NBI (group B) in real time optical diagnosis of colorectal polyps using combined NICE and WASP criteria.Methods: 118 out of 362 patients with 227 polyps were recruited. 62 patients with 130 polyps (3 lost polyps) were assigned to group A and 56 patients with 106 polyps (6 lost polyps) were assigned to group B. Optical diagnoses were compared with pathological reports.Results: The performance of optical diagnosis of neoplastic polyps in group A compared with group B in terms of accuracy, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) was not significantly difference (76%, 72%, 81%, 86%, 64%, in group A, and 71%, 66%, 83%, 90%, 51%, in group B, respectively). Combined NICE and WASP criteria provided all false positive diagnosis of sessile polyps as serrated polyps in 31 (15.9%).Conclusions: Near-focus NBI was not superior to normal-focus NBI in in optical diagnostic of neoplastic polyps using NICE criteria. Combined NICE and WASP classification yielded all false positive in the diagnosis SSAPs in our study. Routine real life optical diagnosis of polyps is still not recommended.Trial registration: Clinical Trials.gov, NCT 04831814, was retrospectively registered on 04/01/2021.

scholarly journals Sa2010 OPTICAL DIAGNOSIS OF SMALL COLORECTAL POLYPS USING OPTIVISTA AND ISCAN IMAGE ENHANCED ENDOSCOPY: A RANDOMIZED CONTROLLED TRIAL

2020 ◽  
Vol 91 (6) ◽  
pp. AB240
Author(s):  
Roupen Djinbachian ◽  
Heiko Pohl ◽  
Paola Marques ◽  
Etienne Marchand ◽  
Célia Hammar ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Colorectal Polyps ◽  
Optical Diagnosis ◽  
Randomized Controlled

scholarly journals The efficacy of aspirin and metformin combination therapy in patients with rectal aberrant crypt foci: a double-blinded randomized controlled trial

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Takuma Higurashi ◽  
Jun Arimoto ◽  
Keiichi Ashikari ◽  
Tomohiro Takatsu ◽  
Noboru Misawa ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Placebo Group ◽  
Controlled Trial ◽  
Colorectal Polyps ◽  
Aberrant Crypt Foci ◽  
Randomized Controlled ◽  
Metformin Group ◽  
Incidence And Mortality ◽  
Chemopreventive Effect ◽  
Oral Aspirin

Abstract Background The incidence and mortality rates of colorectal cancer (CRC) continue to increase worldwide. Therefore, new preventive strategies are needed to lower the burden of this disease. Previous studies reported that aspirin could suppress the development of sporadic colorectal adenoma. In addition, metformin is a biguanide derivative that is long widely used for the treatment of diabetes mellitus and has recently been suggested to have a suppressive effect on carcinogenesis and cancer cell growth. Both drugs exhibit a chemopreventive effect, but their efficacy is limited. Aberrant crypt foci (ACF), defined as lesions containing crypts that are larger in diameter and stain more darkly with methylene blue than normal crypts, are more prevalent in patients with cancer and adenomas, and considered a reliable surrogate biomarker of CRC. Thus, we designed a prospective trial as a preliminary study prior to a CRC chemoprevention trial to evaluate the chemopreventive effect of aspirin combined with metformin on colorectal ACF formation in patients scheduled for polypectomy. Methods This study is a double-blind randomized controlled trial that will be conducted in patients with both colorectal ACF and colorectal polyps scheduled for polypectomy. Eligible patients will be recruited for the study and the number of ACF in the rectum will be counted at the baseline colonoscopy. Then, the participants will be allocated to one of the following two groups; the aspirin plus placebo group or the aspirin plus metformin group. Patients in the aspirin plus placebo group will receive oral aspirin (100 mg) and placebo for 8 weeks, and those in the aspirin plus metformin group will receive oral aspirin (100 mg) and metformin (250 mg) for 8 weeks. After 8 weeks of administration, polypectomy will be performed to evaluate changes in the number of ACF, and the cell-proliferative activity in the normal colorectal mucosa and colorectal polyps. Discussion This is the first study proposed that will explore the effect of aspirin combined with metformin on the formation of colorectal ACF in humans. Trial registration This trial has been registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry as UMIN000028259. Registered 17 July 2017.

Sign in / Sign up

Export Citation Format

Share Document